backBrazil’s health regulatory agency, Anvisa, has issued a public call for scientific studies on the medicinal and pharmaceutical cultivation of Cannabis sativa L., aiming to build the evidence base for a forthcoming regulatory framework. The initiative is strictly technical and collaborative, seeking to compile research already published in recognized journals and repositories, with no funding, prizes or merit evaluation involved. An internal technical committee will review the submitted material and prepare a public report that will guide the drafting of new regulations.
The call follows a decision by Brazil’s Superior Court of Justice, which affirmed Anvisa’s and the federal government’s authority to regulate the cultivation of Cannabis for medicinal use and acknowledged the legality of authorizing the planting and commercialization of industrial hemp, provided that technical standards are respected. By launching the initiative, Anvisa reinforces its commitment to evidence-based decision-making and engagement with the scientific community.
Researchers may submit studies until December 12, 2025, in Portuguese, English or Spanish, covering topics ranging from cannabinoid content and agronomic factors to traceability, quality control and comparative legal analyses.
share
